MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas.

Enami Kaneko Naoki Sato Tae Sugawara Aya Noto Kazue Takahashi Kenichi Makino Yukihiro Terada

Published in: Journal of gynecologic oncology (2021)

In ECs with MMR-D, "met-ECs" were a subgroup with a poorer prognosis than "suspected-LS." "Met-ECs" would be the main target for anti-PD-1 antibody treatment, and its clinical susceptibility should be verified individually.

Keyphrases

tyrosine kinase
dna methylation
gene expression
transcription factor
pulmonary embolism
high grade
replacement therapy
endometrial cancer
combination therapy
clinical trial
phase iii